Back
Speaker illustration

Professor Maciej Wybraniec

School of Medicine in Katowice, Medical University of Silesia, Katowice (Poland)

Member of:

European Society of Cardiology

Prof. Maciej Wybraniec is an interventional cardiologist from Medical University of Silesia in Katowice and Head of Intensive Cardiac Care Unit of Upper Silesian Medical Center in Katowice, Poland. His areas of clinical and scientific expertise are high-risk percutaneous coronary interventions, percutaneous mechanical circulatory support, acute heart failure, cardiorenal syndrome, pharmacological treatment of supraventricular and ventricular arrhythmias and cardiomyopathies. Prof. Maciej Wybraniec is the member of Club 30 of Polish Cardiac Society and currently serves as the Chief of Regional Department of Polish Cardiac Society.

Presentations Articles

Efficacy and safety of antiarrhythmic drugs for pharmacological cardioversion of atrial fibrillation depending on gender: a subanalysis of CANT II Study

Event: ESC Congress 2023

Topic: Antiarrhythmic Drug Treatment

Session: Cardioversion, antiarrhythmics and antithrombotic management of atrial fibrillation

Access
Like
Thumbnail

Clinical characteristics and risk factors of in-hospital mortality among patients undergoing percutaneous pericardiocentesis

Event: ESC Congress 2023

Topic: Complications

Session: Coronary diagnostics and interventions

Access
Like
Thumbnail

Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation and atrial flutter: insights from the LATTEE registry

Event: ESC Congress 2022

Topic: Oral Anticoagulation

Session: Stroke prevention in atrial fibrillation

Access
Like
Thumbnail

Pharmacological cardioversion of recent-onset atrial fibrillation in patients with chronic kidney disease: sub-analysis of the CANT Study

Event: ESC Congress 2021 - The Digital Experience

Topic: Rhythm Control, Cardioversion

Session: Atrial fibrillation e-posters

Access
Like
Thumbnail

CHLD score, a new score based on traditional risk factor evaluation and long-term cardiovascular outcomes in patients with systemic sclerosis

Event: ESC Congress 2021 - The Digital Experience

Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease

Session: Cardiovascular Disease in Special Populations ePosters

Access
Like
Thumbnail

Antazoline for pharmacological cardioversion of atrial fibrillation: the results of the high-volume multicenter CANT study

Event: ESC Congress 2020

Topic: Rhythm Control, Cardioversion

Session: Atrial Fibrillation ePosters

Access
Like
Thumbnail

Managed Care after Acute Myocardial Infarction (MC-AMI) reduces MACE by 45% in 3-month follow-up - results form Poland's National Health Fund program of post-MI care. A single center analysis

Event: ESC Congress 2019

Topic: Secondary Prevention

Session: Risk factors and prevention

Access
Like
Thumbnail

Efficacy of comprehensive Managed Care after Acute Myocardial Infarction (MC-AMI) in a long-term follow-up - preliminary experience of a single high-volume center.

Event: ESC Congress 2019

Topic: Secondary Prevention

Session: Risk factors and prevention

Access
Like
Thumbnail

Propensity score matched analysis of antazoline mesylate vs. amiodarone or propafenone for pharmacological cardioversion of short-duration atrial fibrillation

Event: ESC Congress 2019

Topic: Rhythm Control, Cardioversion

Session: Drug treatment for atrial fibrillation

Access
Like
Thumbnail

Renal resistive index is associated with adverse cardiovascular events at 24 months in patients with coronary artery disease submitted to coronary angiography

Event: ESC Congress 2018

Topic: Noninvasive Diagnostic Methods

Session: Coronary artery disease : diagnosis pharmacotherapy and revascularisation

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources